- Moderate to Severe PC
- Adults, Age 18 or Older
- Able and willing to comply with all protocol-required activities
Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.
We have completed enrollment for the VALO Study, a Phase 2/3 multicenter clinical study evaluating the safety and efficacy of PTX-022 (QTORINTM rapamycin) in adults with moderate to severe pachyonychia congenita (PC). To stay updated on our progress, please complete the form below.